Internationale Partnersuche

Innovation & Technologie Angebot

Irish SME offers new scientific approach to neonatal calf diarrhoea treatment for licensing, manufacturing, commercial distribution agreements.

Country of Origin: Ireland
Reference Number: TOIE20160411001
Publication Date: 18 July 2017

Summary

An Irish based research company focused on developing best in class gastrointestinal treatments for production animal diseases has developed a new to market treatment for neonatal calf diarrhoea. The treatment is formulated to incorporate a novel scientific approach to intestinal and blood biochemistry. Its characterised by full, rapid recovery and low-dose protocols. It is available via a licensing, manufacturing, commercial distribution agreement for South American and Middle-eastern markets.

Description

The research company which specialises in gastrointestinal treatments for production animal diseases has developed this product for neonatal calf diarrhoea which is the most common cause of morbidity and mortality in calves worldwide.  There is scientific uncertainty regarding the optimal treatment for this disease.  Accordingly, a large number of products are commercially available, differentiated by composition and administration protocols. 



Following advanced scientific understanding of the intestinal and blood patho-biochemistry of this disease, the Irish research company has developed a new formulation to treat affected animals.  Built upon novel scientific reasoning and sound peer-reviewed research data, the development of this treatment represents a new class of diarrhoea treatment.



The scientific attributes of the product formulation facilitate corrective action against the key components of the disease simultaneously, thereby facilitating rapid recovery from a low dose rate.  In fact, the treatment has the quickest recovery time and the lowest dose rate available on the market.  



Launched in Ireland in 2015, the product has been independently assessed and used commercially in over 22,000 calves.  Feedback from veterinarians and farmers has been excellent.  Demand has grown from 13,000 treatments (2015) to 150,000 (2016) in Ireland.



Marketed on the basis of 24 hours to recovery and on the basis of a two dose regime, irrespective of the disease severity, the product has found favour for its simplicity and efficacy.  The product has worldwide application, to serve a significant market that is continually expanding on all continents.  



This technology is applicable to a sizeable expanding worldwide market, and is available via a licensing or distribution agreement.  Out-licensing agreements have been recently agreed for Europe, US and Canada.  The company is seeking similar licensing or distribution partners in the South American and Middle-eastern markets, namely: Argentina, Chile, Mexico, Peru & Egypt. Technical veterinary assistance and or training is available.

Advantages and Innovations

Advantages: 

(1) Rapid recovery (24 hours, certified); 

(2) Low dose protocol (two dose, certified, regardless of severity); 

(3) Enhanced buffering capacity; 

(4) Maximum efficacy; 

(5) Suitable to organic farming; 

(6) Classed as a non-medicine; 

(7) Treated calves regain lost production weight (certified); 

(8) Corrects acidosis (certified); 

(9) Corrects dehydration (certified)



Scientific innovation: 

(a) A novel scientific approach to strong ion difference in an oral rehydration and buffering solution (ORBS); 

(b) A novel scientific approach to alkalising agent in an ORBS

(c) Added tocopherol in an ORBS

Stage Of Development

Already on the market

Stage Of Development Comment

On the market in Ireland since 2015.

Requested partner

Animal health, animal nutrition or pharmaceutical companies are required in order to manufacture and commercially distribute the powder-based formula.  



Optionally, veterinary distribution companies to facilitate distribution within the targeted markets..

Dissemination Countries

Argentina, Chile, Egypt, Mexico, Peru